The Valley Desk

NCT03207009 · Interventional trial

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

Overall registry status Completed

Phase 3

Conditions Beta-Thalassemia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov